Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (Biofermentics™)

Ryoichi Shin¹, Momoyo Suzuki¹, Takeo Mizutani¹ and Nobuyuki Susa²

¹Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 and ²Department of Veterinary Public Health, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, 034-8628 Japan

The effects of lactic acid bacteria-fermented soybean extract (Biofermentics™; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of D-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K₂Cr₂O₇) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase. The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

Keywords: anti-oxidation – fermentation – hepatitis – lactobacillus – yeasts

Introduction

It is now a world-wide trend to incorporate dietary supplements into comprehensive medicine (1), and evidence-based medicine (EBM) (2,3), which is required for the recognition and acceptance of these supplements. It has become widely recognized that soybeans contain beneficial components for human health, such as soy protein, peptides, oligosaccharides, phospholipids, isoflavones, saponins, minerals and vitamins (4). The fermentation of soybeans results in various compositional and functional changes, and a large variety of peptides and amino acids are produced from soy protein by different kinds of micro-organisms, which include lactic acid bacteria. Aglycones from isoflavone or saponin glucosides are released by β-glucosidase of fungi and lactic acid bacteria (5,6). The aglycon form of isoflavones and saponins has a higher absorptivity than the glycoside form in humans (7).

There are many traditional soybean products fermented by micro-organisms, particularly in the eastern Asian countries, such as soy sauce (lactobacilli and yeasts) (8), ‘natto’ (Bacillus subtilis natto) (9) and tempeh (Rhizopus sp.) (10). These products are fermented mostly by mold, yeast, bacteria or a combination of these micro-organisms. However, there have been few products fermented exclusively by lactic acid bacteria except a few
recent soymilk products, fermented mostly by the inoculation of a single pure culture of bifidobacteria (11) or lactic acid bacteria (12) as probiotic food.

The purpose of this study was to evaluate the effects of a new dietary supplement, Biofermentics™ (BF), which consists of soymbean fermented by a combination of different species of lactic acid bacteria and yeasts, on in vitro and in vivo hepatic and renal disorder models in rats.

Methods

Preparation of Lactic Acid Bacteria-fermented Soybean Extract (Biofermentics™; BF)

Soymilk was prepared from soybeans of the ‘Tsurunoko’ variety, grown with less agricultural chemicals, in Hokkaido, the northern part of Japan. The soybeans were soaked in water, ground, heated to 98°C for 30 min and expressed through linen. The filtrate was used as soymilk. For fermentation of the soymilk, 12 frozen stock strains of lactic acid bacteria, such as Lactobacillus plantarum, L. casei, L. reuteri and Lactococcus lactis and four strains of the yeast Saccharomyces cerevisiae, were used. Together, the strains were divided into four groups of seed cultures A, B, C and D. Each group consisted of two strains of Lactobacillus, one strain of Lactococcus and one strain of S. cerevisiae. For preparation of the seed cultures, each group of frozen stock was inoculated into the appropriate amount of soymilk and incubated at 37°C for 2 days.

The inoculum sizes were adjusted to $\sim1 \times 10^3$ ml$^{-1}$ and $1 \times 10^4$ ml$^{-1}$ for the lactic acid bacteria and yeast, respectively, based on the predetermined cell numbers in the frozen stock cultures. The four seed cultures were then mixed together, inoculated into a large volume of fresh soymilk of approximately 100 times of the inoculum, and incubated at 37°C for 4 days. The large bulk of fermented soymilk was heated to 98°C for 30 min, cooled to room temperature and extracted by the addition of ethyl alcohol at a final concentration of 14% v/v for about 2 weeks. Then, the extract was separated through filter paper. Both the filtrate and precipitate were used for the different products of lactic acid bacteria-fermented soybean extract (Biofermentics; BF). They were usually freeze-dried.

Rats

Male Wistar rats of 5 weeks of age were purchased from Charles River Co., Tokyo and pre-bred with MF powdery feed (Oriental Yeast Co., Ltd., Tokyo) for a week in a breeding room with a temperature of 23 ± 1°C, humidity of 50 ± 5% and photoperiod cycle of 12 h light/12 h dark.

The care and treatment of rats were done in accordance with the guidelines of institutional animal ethics prescribed by the guidelines of Science Council of Japan for the care and use of laboratory animals.

Oral Administration of BF on Deoxycholic Acid (DCA)-Induced Hepatic and Renal Disorders

At 6 weeks old, the rats were divided into two groups (experimental and control) of 6 rats each, such that the mean and variation of body weights between the two groups were virtually identical. The control group was given MF feed containing exclusively 0.5% DCA (Wako Pure Chemical Industries, Ltd., Osaka) for 6 weeks, while the experimental group was given MF powdery feed containing both 5% BF and 0.5% DCA. Both feed and drinking water were given ad libitum. Blood was collected from the tail vein of each rat at a volume of 0.5 ml at 0, 2, 4 and 6 weeks after the start of the feeding experiment and separated from serum. The concentration of L-asparagine aminotransferase (AST), L-alanine aminotransferase (ALT), blood urea nitrogen (BUN), uric acid (UA) and total cholesterol (T-CHL) in the serum were measured using an enzymic test kit (C-test, Wako; Wako pure Chemical Industries, Ltd., Osaka).

During the final week of the experimental period, each rat was housed in a metabolic cage to measure the daily urine amount excreted and concentrations of electrolytes in the urine. The rats were finally anesthetized in a CO$_2$ bag, their blood immediately collected from the abdominal large vein using a syringe and organs weighed. The collected serum was used to determine the concentrations of total protein (TP), alkali phosphatase (ALP), $\gamma$-glutamyl transpeptidase ($\gamma$-GTP), leucine aminopeptidase (LAP) and glucose (GLU) using multilayer film analytical element, dri-chem colorimetric analyzer 3030 (Fuji Photo Film Co., Ltd., Tokyo), and the concentrations of lipid peroxide (LPO), $\beta$-lipoprotein ($\beta$-LP) and total bile acid (T-BA) were determined using an enzymic test kit (C-test, Wako; Wako pure Chemical Industries, Ltd., Osaka).

Oral Administration of BF on N-Galactosamine (GMN)-Induced Hepatic Disorders

Male Wistar rats of 6 weeks were divided into two groups of similar mean and variation of body weight. One group used as control ($n = 7$) was given MF feed only, while the BF group ($n = 6$) was given MF feed containing 5% BF. Both feed and drinking water were given ad libitum for 3 weeks. At the beginning of the final week of experimental period, all rats were intraperitoneally injected once with a GMN- (Wako Pure Chemical Industries, Ltd., Osaka) solution in a dosage of 500 mg kg$^{-1}$ body wt. Blood was collected from the tail vein in a volume of 0.5 ml, and serum AST activity was
measured on days 1, 2, 3 and 6 following GMN administration.

Estimation of Cytotoxicity

Cytotoxicity caused by exposure to dichromate (K_2Cr_2O_7; Kanto Chemical Co., Tokyo) was estimated by measuring the concentration of lactate dehydrogenase (LDH) leaked from primary cultures of rat hepatocytes and nephrocytes as previously described (13–16). In brief, approximately 2 x 10^6 collagenase-dispersed (Wako pure Chemical Industries, Ltd., Osaka) rat hepatocytes in medium E were plated onto 60-mm diameter Corning Petri dishes (Iwaki Glass, Ltd., Chiba, Japan) and incubated in a humidified atmosphere of 5% CO_2 and 95% air at 37°C for 3 h. Following that, BF was added to the primary culture media at 1.3, 2.5, 5.0 or 10 μM and incubated further for 20 h. The medium was then discarded and the primary cell sheets were overlaid with salt-glucose medium (SGM: 50 mM 4-(2-hydroxyethyl)-1-piperazinesulfonic acid buffer (pH 7.2) with 100 mM K_2Cr_2O_7; Kanto Chemical Co., Tokyo) was estimated in the foregoing section, the cells were washed twice with ice-cold phosphate-buffered saline (PBS) and dislodged from dishes by scraping. The cells were re-suspended in ice-cold PBS and sonicated, and the sonicate was used for the estimation of cellular levels of lipid peroxidation by monitoring MDA formation (20).

Statistical Analysis

The differences between the mean values of the data were evaluated by the Student’s t-test for equal variance or Welch’s t-test for unequal variance. A P-value of less than 0.05 was considered to be statistically significant. Because of the skewed distribution of AST or ALT in rat experiments, data were normalized by logarithmic transformation for further statistical analysis. However, no transformed values were presented in the ‘results’ section.

Results

Improvement of DCA-induced Hepatic and Renal Disorders

As shown in Fig. 1A, in the DCA-administered control group, serum AST activity rapidly increased to 786 ± 475 IU/l at 2 weeks, reached its highest value of 2469 ± 2182 IU/l at 4 weeks, then sharply decreased to 722 ± 502 IU/l at 6 weeks. However, these rapidly increased activities were markedly lowered to 195 ± 105 IU/l, 788 ± 744 IU/l and 147 ± 67 IU/l at 2, 4 and 6 weeks, respectively, in the BF- and DCA-administered group. Thus, the increase of AST activity induced by DCA was clearly reduced by the administration of BF, with reductions significant (P < 0.05) at 2 and 6 weeks. Similarly, in the case of ALT, the increased activity found in controls was also depressed in the BF- administered group (Fig. 1B), with the value at 2 weeks significantly different (P < 0.05) from the DCA-administered control group.

As seen in Table 1, rats in the BF and DCA group showed significantly (P < 0.01) lower serum BUN values at 4 and 6 weeks, as compared with control groups. No significant effects were observed in UA and T-CHL values following BF administration. As for the biochemical analysis of the serum, no clear change between control and BF groups was observed for TP, ALP, γ-GTP, LAP, GLU, LPO and β-LP (Table 2). However, the concentration of T-BA in the serum of the control group (81 ± 36 nmol ml⁻¹) was considerably different from that of BF group (46 ± 34 nmol ml⁻¹). Thus, the BF-administered group tended to show lower concentrations of total bile acid than the control group. Although the amount of urine was found to be larger in the BF group than in the control group, there were no significant differences in urine electrolyte (Na, K and Cl) concentrations.
Amelioration of GMN-induced Hepatic Disorders

As shown in Fig. 2, serum AST activity in the control group increased sharply to 3172 ± 2379 IU/l on day 1 and 2811 ± 2210 IU/l on day 2, then decreased sharply to 372 ± 323 IU/l on day 3 after injection of GMN. In the BF group, AST was significantly \( P < 0.05 \) lowered to 1423 ± 1857, 1009 ± 1395 and 142 ± 161 IU/l on those days, respectively, that is, to ~45% the level of values in the control group.

Cytotoxicity

As shown in Fig. 3, when the hepatocytes were treated with 1 mM dichromate, they were damaged and leaked LDH at a level of 18% of total LDH in normal cells. However, when they were treated with dichromate and BF at the same time, the LDH leakage was significantly inhibited to a level of 7.0% of untreated control cells, indicating that BF treatment had a protective effect against cytotoxicity caused by dichromate treatment. No adverse effects were observed with BF treatment in the range of concentrations employed.

Figure 4 shows that the treatment of nephrocytes with BF at a concentration of more than 2.5 mM for 16 h A

![Figure 1. Effects of oral BF administration on serum AST (A) and ALT (B) activities in rats with hepatic disorders induced by DCA loading. The DCA control group (open square) was given MF powdery feed containing 0.5% DCA only while the DCA and BF group (filled circle) was given MF powdery feed containing both 0.5% DCA and 5% BF. Values indicate mean ± SD \( (n = 6) \). *\( P < 0.05 \) against the respective control values. BF, Biofermentics TM (lactic acid bacteria-fermented soybean extract); AST, L-asparate aminotransferase; ALT, L-alanine aminotransferase; DCA, deoxycholic acid (hepatopathy inducer).

<table>
<thead>
<tr>
<th>Analytical items</th>
<th>DCA-administered group</th>
<th>DCA-and BF-administered group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Total protein (g/dl)</td>
<td>7.0 ± 0.3</td>
<td>7.4 ± 0.3</td>
</tr>
<tr>
<td>Alkali phosphatase (IU/l)</td>
<td>694 ± 143</td>
<td>635 ± 127</td>
</tr>
<tr>
<td>γ-Glutamyl transpeptidase (IU/l)</td>
<td>5.0 ± 1.7</td>
<td>5.2 ± 1.8</td>
</tr>
<tr>
<td>Leucine aminopeptidase (U)</td>
<td>397 ± 199</td>
<td>363 ± 156</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>156 ± 55</td>
<td>172 ± 25</td>
</tr>
<tr>
<td>Lipid peroxide (nmol/ml)</td>
<td>2.3 ± 2.4</td>
<td>1.7 ± 1.4</td>
</tr>
<tr>
<td>β-Lipoprotein (mg/dl)</td>
<td>47 ± 32</td>
<td>53 ± 34</td>
</tr>
<tr>
<td>Total bile acids (nmol/ml)</td>
<td>81 ± 36</td>
<td>46 ± 34</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine excretion (ml/day)</td>
<td>21 ± 14</td>
<td>30 ± 10</td>
</tr>
<tr>
<td>Urine/water intake (%)</td>
<td>56 ± 7</td>
<td>69 ± 18</td>
</tr>
<tr>
<td>Urinary electrolyte (mEq/day): Na</td>
<td>1.4 ± 0.7</td>
<td>2.1 ± 1.1</td>
</tr>
<tr>
<td>K</td>
<td>2.9 ± 1.3</td>
<td>4.6 ± 2.2</td>
</tr>
<tr>
<td>Cl</td>
<td>1.7 ± 0.8</td>
<td>2.7 ± 1.7</td>
</tr>
</tbody>
</table>

DCA, deoxycholic acid; BF, Biofermentics TM (lactic acid bacteria-fermented soybean extract).

Table 1. Biochemical analysis of the serum from DCA-only and DCA-and BF-administered rats

<table>
<thead>
<tr>
<th>Analytical items</th>
<th>Groups</th>
<th>Administration period (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>DCA-administered</td>
<td>27.8 ± 2.3</td>
</tr>
<tr>
<td></td>
<td>DCA- and BF-administered</td>
<td>26.2 ± 1.2</td>
</tr>
<tr>
<td>UA (mg/dl)</td>
<td>DCA-administered</td>
<td>2.2 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>DCA- and BF-administered</td>
<td>2.2 ± 0.5</td>
</tr>
<tr>
<td>T-CHL (mg/dl)</td>
<td>DCA-administered</td>
<td>69 ± 11</td>
</tr>
<tr>
<td></td>
<td>DCA- and BF-administered</td>
<td>78 ± 11</td>
</tr>
</tbody>
</table>

*\( P < 0.05 \) compared to the corresponding value of the DCA administered group.

BF, Biofermentics TM (lactic acid bacteria-fermented soybean extract); BUN, blood urea nitrogen; UA, uric acid; T-CHL, total cholesterol; DCA, deoxycholic acid.
also revealed the tendency to suppress \( P < 0.07 \) cytotoxicity caused by dichromate.

**Lipid Peroxidation**

As shown in Fig. 5, the treatment of hepatocytes with 1 mM dichromate alone for 8 h revealed a significant increase \( P < 0.05 \) in MDA formation of 1.7 nmol mg\(^{-1}\) protein, when compared with MDA formation of 0.3 nmol mg\(^{-1}\) protein for the control cells without any treatment. However, when the cells were treated with BF at concentrations of 5 or 10 \( \mu \)l/ml combined with dichromate, significant (50% or more) inhibitions \( P < 0.05 \) of MDA formation was observed, indicating that BF treatment exhibited a protective effect against cytotoxicity caused by dichromate. No increase in MDA formation occurred among cells treated with BF alone in the test range of 1.3–10 \( \mu \)l/ml.

**Discussion**

DCA, a secondary bile acid, is highly toxic and causes cholestatic hepatopathy in experimental animals (21). When the concentration of bile acids exceeds the binding...
capacity of binding proteins located in the cytosol of the hepatocytes, bile acids induce apoptosis and necrosis by damaging mitochondria (22). Hydrophobic bile acids induce alterations in membrane fluidity associated with impairment of mitochondrial respiration and depolarization. In this study, it was considered that the suppression of bile acid concentration in hepatocytes was one of the mechanisms for BF to reduce the damage to hepatocytes. We found that the BF administered group tended to show lower values of total bile acid concentration in serum than control groups (Table 2). As a reason why the concentration of bile acid in hepatocytes was suppressed by BF, it is suspected that the absorption of DCA by intestinal mucosa was decreased by inhibiting the conjugation of bile acids with amino acids and by lowering the active transportation activity of bile acids in intestinal mucosa, though this supposition is unclear and requires further study.

In a model of human viral hepatitis, GMN inhibits the protein and the nucleic acid synthesis of hepatocytes (23,24). It has been reported that various kinds of dietary amino acids, such as L-serine, L-asparagine, L-histidine, L-lysine, L-tyrosine, L-glycine and L-glutamine, were effective in protecting rats from GMN-induced injury (25). Moreover, the effects of oligosaccharides and dietary fiber have been shown to prevent GMN-induced hepatic injury (26). Therefore, we believe that amino acids and oligosaccharides, ingredients of BF originating from soymilk, are partly attributable to protection against GMN-induced hepatic disorders.

Hexavalent chromium is reduced to stable form of trivalent chromium in hepatic and renal cells (15). It has been considered that the active oxygen (hydroxyl radical •OH) produced in these cells causes damage to the cell membrane and DNA through lipid peroxidation, which leads to leakage of LDH in the cell. It has also been reported that aglycones from saponin or isoflavone glycosides, both ingredients of soymilk, are released by β-glucosidase of lactic acid bacteria (5,6). As such, we suspect that the anti-oxidative powers of BF were conserved in the process of fermentation by the mixed culture of the lactic acid bacteria and yeast in this study. Therefore, the anti-oxidative effect of BF prevented lipid peroxidation by chromium, and we believe that the power of BF as an anti-oxidant is similar to that of a lot of other anti-oxidation substances such as catechin, chlorogenic acid, vitamin E and melatonin, as previously tested (14,15,19). There have been many reports about the therapeutic benefits of plant herbs and fruits, notably on their anti-oxidant properties (27–29). Accordingly, taking fermented soybean extract, such as the BF used in this article, as an anti-oxidant every day may contribute to better overall health of humans.

There have been reports about the functionality of the soybean as fermented by different micro-organisms (30,31). Moreover, it has been postulated that products of fermentation with two or more bacteria, are considerably more complicated than those with a single kind of bacterium (32,33). Although we did not examine the fermentation products of each bacterium used for the production of BF in this experiment, further study is needed for both single and co-cultivation to isolate the specific fermentation products responsible for the anti-oxidative effects of BF.

In conclusion, this study suggests that BF may be applied to an improvement of hepatic and renal disorders, BF may also possess other health benefits in humans.

Acknowledgement

We are grateful for the review of this article from the clinical standpoint by Dr Morie Sekiguchi (M.D., Ph. D., F.A.C.C.).

References


Submit your manuscripts at http://www.hindawi.com